Photo: Tima Miroshnichenko / Pexels
Noetix Robotics files confidentially for Hong Kong IPO to raise hundreds of millions
The Beijing humanoid robot maker behind the $1,400 Bumi is lining up a public listing that could come as early as 2027
Noetix Robotics, a Beijing startup that builds humanoid robots, has filed confidentially for an initial public offering in Hong Kong. The company is looking to raise several hundred million dollars, according to Bloomberg.
The filing was reported on October 21, 2026. A public listing is anticipated as early as 2027.
From dorm-room idea to IPO paperwork
On paper, the company goes by Songyan Power Beijing Technology Co., Ltd. The market knows it as Noetix Robotics.
Jiang Zheyuan founded the company after dropping out of Tsinghua University.
Noetix has raised over $200 million across nine funding rounds.
The biggest of those was a Series B completed in March 2026. That round brought in approximately $138 to $145 million and valued the company at around $550 million.
Chendao Capital led the round. Chendao is a firm associated with CATL, the battery manufacturer that supplies much of the electric vehicle industry.
The filing was made confidentially. The company’s draft prospectus and financial details are not public.
AI, tech, and the markets they move—in one daily briefing.
Daily. Free. Join 34,000+ readers across crypto, finance, and policy.
A robot priced like a laptop
In late 2025, Noetix launched the Bumi, a consumer humanoid priced at around 9,988 yuan, or about $1,400.
The company says it can produce the Bumi at scale. Production capacity has reached dozens of units per day.
Noetix also sells more advanced platforms. The N2 and E1 are aimed at athletic and research uses.
The N2 placed second in a humanoid robot half-marathon in 2025.
Noetix appeared at the 2026 CCTV Spring Festival Gala.
The company has leaned into education alongside consumer sales. It also aims to capture international markets including North America and Europe.
Why the listing matters
Private investors valued the company at around $550 million in March 2026. A raise of several hundred million dollars implies public investors would need to see meaningfully more value than that to make the math work without heavy dilution.
The low-cost strategy cuts both ways. Selling a humanoid for around $1,400 could open a mass market that pricier rivals cannot reach. It also means thin room for error on manufacturing costs, especially as the company scales beyond dozens of units per day.
A listing is anticipated as early as 2027.